About trastuzum ab
HER2-targeted monoclonal antibody
Used for
- HER2-positive breast cancer
- HER2-positive stomach or gastroesophageal junction cancer
Usual adult dose
Usually 8 mg/kg IV loading dose, then 6 mg/kg every 3 weeks for breast cancer; schedules vary by cancer and regimen.
Common side effects
- Infusion reactions, including fever or chills
- Heart problems, including reduced heart function
- Diarrhea
- Nausea or rash
Important warnings
- Heart function should be assessed before and during treatment.
- Infusion reactions can be severe, especially during the first dose.
- May cause serious harm to an unborn baby.
- Use only for cancers confirmed to be HER2-positive.
Pregnancy
Can cause fetal harm. Avoid pregnancy during treatment and for 7 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 7 months after the last dose.
Interactions
- Anthracycline chemotherapy can increase heart damage risk, including when given after trastuzumab.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.